US stocks: Summit shares drop after US FDA declines to approve lung cancer drug

Summit Therapeutics faced a notable decline in share value following the FDA's ruling on ivonescimab, which revealed insufficient overall survival benefits during late-stage trials. Despite Summit's emphasis on regional survival differences, analy...

Agencies
Shares of Summit Therapeutics fell 14% on Monday after the US Food and Drug Administration declined to approve its experimental lung cancer drug ivonescimab.

The regulator on Sunday cited the drug's failure to achieve statistically significant overall survival benefit in a late-stage study that was part of Summit's application.

Follow-up data reported last year also pointed to a greater survival benefit in Chinese patients than those from North America and Europe, although Summit later submitted statistically significant overall survival results from a longer follow-up with consistent improvement across Western and Asian populations.


The FDA's decision sets a "meaningful regulatory precedent" for the drug class, with potential implications for similar drugs being developed by Bristol Myers Squibb, BioNTech , Pfizer, Merck and AbbVie, said BMO Capital analyst Evan Seigerman.

Ivonescimab targets proteins PD-1 and VEGF, which help tumors evade the immune system and spread.

Summit's shares were down 14% at $12.16 in morning trading.
ADVERTISEMENT

Summit had sought approval for ivonescimab, in combination with chemotherapy, for previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutations, which account for about 10% to 15% of US cases.

Investors now await data due later this year from a separate global late-stage trial comparing ivonescimab against Merck's blockbuster Keytruda as a first-line treatment for NSCLC.

"I'm still encouraged by the PD-(L)1/VEGF class," with first-line data due for ivonescimab, Bristol Myers and BioNTech's pumitamig, and others, said Adam Schoenfeld, a thoracic oncologist at Memorial Sloan Kettering Cancer Center.

"These therapies could substantially change practice for patients with lung cancer whose tumors do not have an EGFR mutation," Schoenfeld added.
ADVERTISEMENT

The FDA decision does not alter ivonescimab's prospects in first-line NSCLC, "the substantially larger and more important commercial opportunity," TD Cowen analysts said.

Summit acquired rights to the drug in the US, Canada, Europe and Japan from China's Akeso in 2022.
ADVERTISEMENT
READ MORE

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Markets › US Stocks › News › US stocks: Summit shares drop after US FDA declines to approve lung cancer drug
Text Size:AAA
Success
This article has been saved

*

+